Dual Inhibition In The RELAY Trial In Patients With EGFR mut + Advanced NSCLC

Dr. Kazuhiko Nakagawa explains the detailed mechanism of action on how ramucirumab plus erlotinib increases the progression-free survival and duration of response in epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC) patients.1,2  References 1. Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, Zhan P, Song Y. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Translational Lung Cancer Research. 2019 Jun;8(3):302.

2. Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomized, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2019 Dec 1;20(12):1655-69.